TerraBioGen Announces Shares for Debt Settlement

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWS
AGENCIES


TerraBioGen Technologies Inc. ("TerraBioGen") (TSX VENTURE:TBG), a developer and
marketer of proprietary technologies for the production of organic-based,
high-value agricultural products from organic wastes, announces that it has
settled $430,000 of amounts payable in exchange for 5,375,000 common shares at
$0.08 per share and 3,875,000 warrants exercisable at $0.15 for two years.
Completion of the transaction is subject to the approval of the TSX Venture
Exchange. 


The debt settlement was negotiated with Recondo Holdings Ltd. ("Recondo") in
conjunction with an extension of a Master License Agreement ("MLA") with Recondo
for 2 years. The MLA provides Recondo with the exclusive rights to construct and
operate TerraBioGen plants within the Republic of Ireland and Northern Ireland
and the non-exclusive rights to construct and operate TerraBioGen plants in the
United Kingdom of Great Britain. The extension of the MLA will expire on
December 31, 2013.


Blair Heffelfinger, President and CEO of TerraBioGen, stated that he is pleased
to reach this agreement with Recondo. "Recondo is a strategic partner of the
Company, facilitating access to the agriculturally progressive markets of
Ireland and the UK. At the same time, the conversion of the amounts payable into
shares is another step in the company's debt restructuring and will further
improve our balance sheet and working capital." 


About TerraBioGen 

Located in North Vancouver, BC, TerraBioGen Technologies Inc. is committed to
research and development to continue to improve the efficiency of its technology
and the quality of its agricultural products. It is further committed to
developing a world-wide marketing capability to ensure market acceptance of its
products.


This news release contains certain statements that may be deemed
"forward-looking" statements. Forward looking statements are statements that are
not historical facts and are generally, but not always, identified by the words
"expects", "plans", "anticipates", "believes", "intends", "estimates",
"projects", "potential" and similar expressions, or that events or conditions
"will", "would", "may", "could" or "should" occur. Although TerraBioGen believes
the expectations expressed in such forward-looking statements are based on
reasonable assumptions, such statements are not guarantees of future performance
and actual results may differ materially from those in forward looking
statements. Forward looking statements are based on the beliefs, estimates and
opinions of TerraBioGen's management on the date the statements are made. Except
as required by law, TerraBioGen undertakes no obligation to update these
forward-looking statements in the event that management's beliefs, estimates or
opinions, or other factors, should change.


THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR
DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES,
AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF
1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD
IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.

Terrabiogen Technologies (TSXV:TBG)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024